These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 14599854

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J, Marcén R, Ortuño J.
    Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract] [Full Text] [Related]

  • 23. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Sep; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.
    Li J, Li X, Tan M, Lin B, Hou S, Qian W, Li B, Zhang D, Zhou B, Wang H, Zhu T, Guo Y.
    MAbs; 2009 Sep; 1(1):49-55. PubMed ID: 20046574
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR, Faulds D.
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [Abstract] [Full Text] [Related]

  • 29. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
    Baldassari LE, Rose JW.
    Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
    Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, Sherr A, Gottlieb AB.
    J Am Acad Dermatol; 2000 Sep; 43(3):448-58. PubMed ID: 10954656
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. CD25 saturation rate in heart transplant patients receiving two-dose daclizumab induction.
    Potter BJ, Giannetti N, Routy JP, Cecere R, Cantarovich M.
    Transplantation; 2005 Apr 15; 79(7):857-8. PubMed ID: 15818335
    [No Abstract] [Full Text] [Related]

  • 34. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab.
    Egan CA, Brown M, White JD, Yancey KB.
    Clin Immunol; 2001 Nov 15; 101(2):146-51. PubMed ID: 11683573
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Daclizumab.
    Mottershead M, Neuberger J.
    Expert Opin Biol Ther; 2007 Oct 15; 7(10):1583-96. PubMed ID: 17916050
    [Abstract] [Full Text] [Related]

  • 39. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.
    Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S.
    Blood; 2000 Jan 01; 95(1):83-9. PubMed ID: 10607689
    [Abstract] [Full Text] [Related]

  • 40. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
    Chen J, Zhang M, Ju W, Waldmann TA.
    Blood; 2009 Feb 05; 113(6):1287-93. PubMed ID: 18948574
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.